Maria Spinoso
School · Baldwin, NYNPI 1710492723
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 30.4% of the total. Among school clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$550
- Lilly USA, LLC$382
- Sanofi-aventis U.S. LLC$284
- Alkermes, Inc.$236
- AstraZeneca$184
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,170100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $1,272 |
| Novo Nordisk | 26 | $550 |
| Lilly USA, LLC | 21 | $382 |
| Sanofi-aventis U.S. LLC | 5 | $284 |
| Alkermes, Inc. | 7 | $236 |
| AstraZeneca | 10 | $184 |
| Amgen(2 entities) | 12 | $181 |
| Indivior Inc. | 6 | $135 |
| Nestle Healthcare Nutrition Inc. | 4 | $96 |
| Gilead | 4 | $92 |
| Inspire Medical Systems, Inc. | 3 | $60 |
| GSK | 3 | $58 |
| Ardelyx, Inc. | 2 | $53 |
| Eisai Inc. | 2 | $52 |
| Renalytix AI, Inc. | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Pfizer | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Bayer | 2 | $39 |
| Orexo US, Inc. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Philips North America LLC | 1 | $31 |
| Medtronic | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| Antares Pharma, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Shield Therapeutics Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$125
- VRAYLAR$125
- Wegovy$119
- TOUJEO$118
- SOLIQUA 100/33$118
How this compares
$4,185 in reported general payments places this provider in the 95th percentile of 23 school providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $21,661 |
| FarxigaDapagliflozin Propanediol | 16 | $13,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,132 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 31 | $2,751 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,630 |
| Levothyroxine Sodium | 121 | $1,540 |
| Buprenorphine Hcl | 14 | $1,384 |
| Rosuvastatin Calcium | 78 | $1,025 |
| Atorvastatin Calcium | 146 | $1,020 |
| Amlodipine Besylate | 122 | $1,020 |
| Ezetimibe | 20 | $912 |
| Losartan Potassium | 104 | $755 |
| Metoprolol Succinate | 59 | $723 |
| Omeprazole | 58 | $627 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 27 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $550 | $21,66124 claims |
| AstraZenecaFarxiga | $184 | $13,82016 claims |
| GSKTrelegy Ellipta | $58 | $7,13211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 23 school providers in New York.
Other school in Baldwin
- Susan ButlerBuffalo$1K
- Sandra BaffourBrooklyn$889
- Geetha AjaySouth Ozone Park$830
- Sarah GoldbergNew York$335
- Ellen JohnsonHopewell Junction$172
- Bethany MooreWilliamson$75
- Abiola DaramolaBronx$74
- Jodi-Kaye McGhieWhite Plains$73
- Colleen AmidonHornell$72
- Ann SangerHilton$52
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.